«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《国际消化病杂志》[ISSN:1673-534X/CN:31-1953/R]

期数:

2024年06期

页码:

381-386

栏目:

论著

出版日期:

2024-12-20

文章信息/Info

Title:

Serum levels of miR-22 and miR-335 in patients with ulcerative colitis and their association with disease severity and prognosis

作者:

张晨华; 毛珍珍; 刘 靖; 卢军仪; 许伟光; 王 婧

061000 河北省沧州中西医结合医院消化科（张晨华、毛珍珍），老年胃肠病科（刘靖、卢军仪），中医科（许伟光、王婧）

Author(s):

ZHANG Chenhua;  MAO Zhenzhen; LIU Jing;  LU Junyi; XU Weiguang;  WANG Jing

ZHANG Chenhua, MAO Zhenzhen. Department of Gastroenterology, Hebei Cangzhou Integrated Traditional Chinese and Western Medicine Hospital, Cangzhou 061000, China; LIU Jing, LU Junyi. Department of Elderly Gastroenterology, Hebei Cangzhou Integrated Traditional Chinese and Western Medicine Hospital, Cangzhou 061000, China; XU Weiguang, WANG Jing. Department of Traditional Chinese Medicine, Hebei Cangzhou Integrated Traditional Chinese and Western Medicine Hospital, Cangzhou 061000, China

关键词:

溃疡性结肠炎; miR-22 ; miR -335 ; 病情; 预后

Keywords:

Ulcerative colitis;  miR-22;  miR-335;  Disease severity;  Prognosis

分类号:

-

DOI:

10.3969/j.issn.1673-534X.2024.06.007

文献标识码:

-

摘要:

目的探究溃疡性结肠炎（UC）患者的血清miR-22和miR-335表达水平及其与病情严重程度、预后的相关性。方法选择2019年7月至2021年7月在河北省沧州中西医结合医院治疗的115例UC患者设为病例组，根据病情严重程度将UC患者分为轻度UC组（n＝46），中度UC组（n＝38）和重度UC组（n＝31）。根据UC患者预后情况分为预后不良组（n＝23）和预后良好组（n＝92）。另选择同期来该院的115名健康体检者设为对照组。采用实时荧光定量PCR法检测各组的血清miR-22和miR-335表达水平。采用ROC曲线分析血清miR-22和miR-335诊断重度UC及预测UC患者预后不良的价值。结果病例组的血清miR-22和miR-335表达水平均较对照组显著降低（P均＜0.05）。轻度UC组、中度UC组和重度UC组的血清miR-22和miR-335表达水平逐渐降低，差异均有统计学意义（P均＜0.05）。ROC曲线分析结果显示，血清miR-22和miR-335单独及联合诊断重度UC的曲线下面积（AUC）分别为0.803、0.813和0.907，2项联合诊断的效能分别优于单独诊断（Z＝2.015，Z＝1.851，P均＜0.05）。预后不良组的血清miR-22和miR-335表达水平较预后良好组均显著降低（P均＜0.05）。ROC曲线分析结果显示，血清miR-22和miR-335单独及联合预测UC患者预后不良的AUC分别为0.794、0.807和0.938，2项联合预测的效能分别优于单独预测（Z＝2.470，Z＝2.524，P均＜0.05）。结论UC患者的血清miR-22和miR-335均呈低表达，血清miR-22和miR-335均有潜力作为UC患者病情严重程度评估及预后预测的指标。

Abstract:

Objective? This paper aims to investigate the expression levels of serum miR-22 and miR-335 in patients with ulcerative colitis (UC) and their correlation with disease severity and prognosis. Methods? A total of 115 UC patients treated at Hebei Cangzhou Integrated Traditional Chinese and Western Medicine Hospital from July 2019 to July 2021 were selected as the case group. Based on disease severity, the UC patients were divided into the mild UC group (n＝46), the moderate UC group (n＝38), and the severe UC group (n＝31). According to the prognosis, they were further divided into a poor prognosis group(n＝23) and a good prognosis group (n＝92). Another 115 healthy individuals from the same period in the hospital were selected as the control group. Real time fluorescence quantitative PCR was used to detect the expression levels of serum miR-22 and miR-335 in each group. ROC curve analysis was performed to evaluate the diagnostic value of serum miR-22 and miR-335 for severe UC and their ability to predict poor prognosis in UC patients. Results? The expression levels of serum miR-22 and miR-335 in the case group are significantly lower than those in the control group (P＜0.05). The expression levels of both serum miR-22 and miR-335 gradually decrease in the mild UC group, the moderate UC group, and the severe UC group, with statistically significant differences (P＜0.05). The ROC curve analysis reveals that the area under the curve (AUC) for serum miR-22 and miR-335 in diagnosing severe UC, both individually and combined, are 0.803, 0.813, and 0.907, respectively. The combination of both biomarkers has a higher diagnostic efficacy than either biomarker alone (Z＝2.015, Z＝1.851, P＜0.05). The expression levels of serum miR-22 and miR-335 in the poor prognosis group are significantly lower than those in the good prognosis group (P＜0.05). The ROC curve analysis shows that the AUC for serum miR-22 and miR-335, both individually and combined, for predicting poor prognosis in UC patients are 0.794, 0.807, and 0.938, respectively. Again, the combined prediction is more effective than the individual predictions (Z＝2.470, Z＝2.524, P＜0.05). Conclusion? Serum miR-22 and miR-335 in UC patients are downregulated and have the potential to serve as biomarkers for assessing disease severity and predicting prognosis in UC patients.

参考文献/References

1Kucharzik T, Koletzko S, Kannengiesser K, et al. Ulcerative colitis-diagnostic and therapeutic algorithms[J]. Dtsch Arztebl Int, 2020, 117(33-34): 564-574.
2Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update[J]. Clin Med (Lond), 2021, 21(2): 135-139.
3Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis[J]. Nat Rev Dis Primers, 2020, 6(1): 74.
4Kaenkumchorn T, Wahbeh G. Ulcerative colitis: Making the diagnosis[J]. Gastroenterol Clin North Am, 2020, 49(4): 655-669.5Yarani R, Shojaeian A, Palasca O, et al. Differentially expressed miRNAs in ulcerative colitis and Crohn's disease[J]. Front Immunol, 2022, 13: 865777.
6 谢春燕, 谢刚, 季语竹. 柚皮素通过miR-22抑制NLRP3炎症小体并减轻溃疡性结肠炎大鼠模型肠屏障损伤[J]. 中国病理生理杂志, 2021, 37(9): 1573-1581.
7Sun Y, Cai D, Hu W, et al. Identifying hub genes and miRNAs in Crohn's disease by bioinformatics analysis[J]. Front Genet, 2022, 13:950136.
8 中华医学会消化病学分会炎症性肠病学组, 钱家鸣, 吴开春. 炎症性肠病诊断与治疗的共识意见（2018 年，北京）[J]. 中国消化杂志, 2018, 38(5): 292-311.
9Sun Y, Zhang Z, Zheng CQ, et al. Mucosal lesions of the upper gastrointestinal tract in patients with ulcerative colitis: A review[J]. World J Gastroenterol, 2021, 27(22): 2963-2978.
10 Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis[J]. Lancet, 2023, 402(10401): 571-584.
11 路敏敏, 王俊, 孙振林, 等. 血清miR-590联合粪便钙卫蛋白对溃疡性结肠炎的诊断价值及其与内镜下疾病活动度的相关性[J].国际消化病杂志, 2024, 44(3): 196-199.
12 Zhou J, Liu J, Gao Y, et al. miRNA-based potential biomarkers and new molecular insights in ulcerative colitis[J]. Front Pharmacol, 2021, 12: 707776.
13 Jung H, Kim JS, Lee KH, et al. Roles of microRNAs in inflammatory bowel disease[J]. Int J Biol Sci, 2021, 17(8): 2112-2123.
14 Tang S, Guo W, Kang L, et al. MiRNA-182-5p aggravates experimental ulcerative colitis via sponging Claudin-2[J]. J Mol Histol, 2021, 52(6): 1215-1224.
15 Guo J, Zhang R, Zhao Y, et al. MiRNA-29c-3p promotes intestinal inflammation via targeting leukemia inhibitory factor in ulcerative colitis[J]. J Inflamm Res, 2021, 14: 2031-2043.
16 Yang QY, Yang KP, Li ZZ. MiR-22 restrains proliferation of rheumatoid arthritis by targeting IL6R and may be concerned with the suppression of NF-κB pathway[J]. Kaohsiung J Med Sci, 2020, 36(1): 20-26.
17 Sun R, Liu Z, Han L, et al. miR-22 and miR-214 targeting BCL9L inhibit proliferation, metastasis, and epithelial-mesenchymal transition by down-regulating Wnt signaling in colon cancer[J]. FASEB J, 2019, 33(4): 5411-5424.
18 Youn GS, Park JK, Lee CY, et al. MicroRNA-22 negatively regulates LPS-induced inflammatory responses by targeting HDAC6 in macrophages[J]. BMB Rep, 2020, 53(4): 223-228.
19 杨文宏, 孙惠芳, 杨洁. miR-125b和miR-335在炎症性肠病患者外周血和肠黏膜中的表达研究[J]. 重庆医学, 2021, 50(5): 800-805.
20 张云青, 王健, 阳春华, 等. miR-335-5p靶向程序化细胞死亡基因5对骨关节炎软骨细胞增殖、凋亡的影响[J]. 中国组织工程研究, 2021, 25(14): 2142-2147.
21 牛帅帅, 孙卓伟, 王承群. 绞股蓝皂苷A调控lncRNA TTTY15/miR-335-5p通路对骨关节炎软骨细胞损伤的影响及机制[J]. 河北医药, 2022, 44(7): 981-985.

备注/Memo

备注/Memo:

基金项目：河北省中医药类科学研究课题计划项目（2024178）

常用功能

更新日期/Last Update: 2024-12-20